Literature DB >> 20444437

Stabilizing formulations for inhalable powders of an adenovirus 35-vectored tuberculosis (TB) vaccine (AERAS-402).

Tom H Jin1, Eric Tsao, Jaap Goudsmit, Veerabadran Dheenadhayalan, Jerald Sadoff.   

Abstract

A powder vaccine intended for aerosol delivery was formulated by spray drying the Ad35-vectored tuberculosis (TB) AERAS-402 vaccine with mannitol-based stabilizers. Thermodynamic properties, water absorption, particle size distribution and morphology of the powders were evaluated. Virus survival during spray drying and storage was determined by medium Tissue Culture Infectious Dose (TCID(50)). A mannitol-based powder (mannitol-cyclodextrin-trehalose-dextran, MCTD) had a narrow size distribution with a median volume diameter around 3.2-3.5microm (suitable for pulmonary vaccination of humans) and good aerosolization characteristics. The spray dry powders generated from mannitol-based formulations were hydrophobic, which benefits virus survival during both production and storage at 4 degrees C, 25 degrees C and 37 degrees C as compared to the hygroscopic formulations (trehalose, sucrose, dextran, PVP, leucine). In conclusion, this study demonstrates that it is possible to produce in a one-step spray drying process a stable dry powder formulation of a TB vaccine suitable for mass vaccination.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20444437     DOI: 10.1016/j.vaccine.2010.04.059

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.

Authors:  Ebenezer Tumban; Pavan Muttil; Carolina Andrea A Escobar; Julianne Peabody; Denis Wafula; David S Peabody; Bryce Chackerian
Journal:  Vaccine       Date:  2015-05-21       Impact factor: 3.641

2.  A nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 vaccine: Evidence for transient t cell responses in peripheral blood and robust sustained responses in the lungs.

Authors:  David A Hokey; Robert Wachholder; Patricia A Darrah; Diane L Bolton; Dan H Barouch; Krystal Hill; Veerabadran Dheenadhayalan; Stephan Schwander; C Steven Godin; Macaya Douoguih; Maria Grazia Pau; Robert A Seder; Mario Roederer; Jerald C Sadoff; Donata Sizemore
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 3.  Nanocarriers targeting dendritic cells for pulmonary vaccine delivery.

Authors:  Nitesh K Kunda; Satyanarayana Somavarapu; Stephen B Gordon; Gillian A Hutcheon; Imran Y Saleem
Journal:  Pharm Res       Date:  2012-10-09       Impact factor: 4.200

4.  Stabilization of HAC1 influenza vaccine by spray drying: formulation development and process scale-up.

Authors:  Changcheng Zhu; Yoko Shoji; Scott McCray; Michael Burke; Caitlin E Hartman; Jessica A Chichester; Jeff Breit; Vidadi Yusibov; Dexiang Chen; Manjari Lal
Journal:  Pharm Res       Date:  2014-05-24       Impact factor: 4.200

Review 5.  Challenges and future in vaccines, drug development, and immunomodulatory therapy.

Authors:  Heather M Kling; Gerard J Nau; Ted M Ross; Thomas G Evans; Krishnendu Chakraborty; Kerry M Empey; JoAnne L Flynn
Journal:  Ann Am Thorac Soc       Date:  2014-08

6.  Optimized Formulation of a Thermostable Spray-Dried Virus-Like Particle Vaccine against Human Papillomavirus.

Authors:  Sugandha Saboo; Ebenezer Tumban; Julianne Peabody; Denis Wafula; David S Peabody; Bryce Chackerian; Pavan Muttil
Journal:  Mol Pharm       Date:  2016-04-11       Impact factor: 4.939

7.  Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge.

Authors:  Thomas W Geisbert; Michael Bailey; Lisa Hensley; Clement Asiedu; Joan Geisbert; Daphne Stanley; Anna Honko; Joshua Johnson; Sabue Mulangu; Maria Grazia Pau; Jerome Custers; Jort Vellinga; Jenny Hendriks; Peter Jahrling; Mario Roederer; Jaap Goudsmit; Richard Koup; Nancy J Sullivan
Journal:  J Virol       Date:  2011-02-16       Impact factor: 5.103

8.  A stable live bacterial vaccine.

Authors:  Nitesh K Kunda; Denis Wafula; Meilinn Tram; Terry H Wu; Pavan Muttil
Journal:  Eur J Pharm Biopharm       Date:  2016-03-25       Impact factor: 5.571

9.  Design and Optimization of a Temperature-Stable Dry Powder BCG Vaccine.

Authors:  Dominique N Price; Nitesh K Kunda; Rajaun Ellis; Pavan Muttil
Journal:  Pharm Res       Date:  2019-12-23       Impact factor: 4.580

10.  Intratracheal inoculation of AHc vaccine induces protection against aerosolized botulinum neurotoxin A challenge in mice.

Authors:  Changjiao Gan; Wenbo Luo; Yunzhou Yu; Zhouguang Jiao; Sha Li; Duo Su; Junxia Feng; Xiaodong Zhao; Yefeng Qiu; Lingfei Hu; Dongsheng Zhou; Xiaolu Xiong; Jinglin Wang; Huiying Yang
Journal:  NPJ Vaccines       Date:  2021-06-22       Impact factor: 7.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.